EP Patent

EP2831073B1 — Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases

Assigned to Rhizen Pharmaceuticals AG · Expires 2020-12-09 · 5y expired

What this patent protects

Patent listed against cabozantinib-s-malate.

Drugs covered by this patent

Patent Metadata

Patent number
EP2831073B1
Jurisdiction
EP
Classification
—
Expires
2020-12-09
Drug substance claim
No
Drug product claim
No
Assignee
Rhizen Pharmaceuticals AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.